| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 456 | 452 | 0 | 107 | 2.234 | 645 | 631 | 847 | 71 | 71 |
| Gross Profit/Loss - EUR | -456 | -452 | 0 | -107 | -2.234 | -645 | -631 | -847 | -71 | -71 |
| Net Profit/Loss - EUR | -456 | -452 | 0 | -107 | -2.234 | -645 | -631 | -847 | -71 | -71 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Nobel Ilac Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 636 | 629 | 618 | 500 | 473 | 543 | 309 | 501 | 500 | 497 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 443 | 0 | 431 | 484 | 474 | 465 | 455 | 456 | 455 | 453 |
| Cash | 192 | 190 | 187 | 16 | -1 | 78 | -146 | 45 | 45 | 45 |
| Shareholders Funds | -51.185 | -50.663 | -49.806 | -48.999 | -50.284 | -49.976 | -49.089 | -49.456 | -49.377 | -49.173 |
| Social Capital | 1.125 | 1.113 | 1.095 | 1.074 | 1.054 | 1.034 | 1.011 | 1.014 | 1.011 | 1.005 |
| Debts | 51.821 | 51.292 | 50.424 | 49.499 | 50.758 | 50.519 | 49.399 | 49.957 | 49.877 | 49.670 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Nobel Ilac Med Srl